Want to see DE:MRK full AI Analyst Report?
MRK Stock Chart & Stats
€118.50
-€0.25(-0.17%)
At close: 4:00 PM EST
€118.50
-€0.25(-0.17%)
Day’s Range― - ―
52-Week Range€100.70 - €148.65
Previous CloseN/A
Volume8.13K
Average Volume (3M)321.00K
Market Cap
€60.74B
Enterprise Value€67.29B
Total Cash (Recent Filing)€3.77B
Total Debt (Recent Filing)€12.04B
Price to Earnings (P/E)24.0
Beta0.95
Next Earnings
Aug 06, 2026Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)5.82
Shares Outstanding129,242,250
10 Day Avg. Volume344,164
30 Day Avg. Volume321,004
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€141.14Price Target Upside19.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)7.97
Revenue Forecast (FY)€21.07B
Bulls Say, Bears Say
Bulls Say
Durable Profitability / High MarginsConsistently high gross and operating margins indicate durable pricing power and a favorable product mix across segments. These margins provide a structural buffer against volume swings, support long-term cash generation, and enable sustained reinvestment in R&D and capital projects.
Diversified Business ModelA three‑pillar business model spreads cyclicality across Healthcare, Life Science and Electronics. Recurring consumables and qualification-led sales in Life Science, regulated/patented healthcare products and specialty materials in Electronics reduce reliance on any single market and support revenue stability.
Manageable Leverage And Balance-Sheet ResilienceModerate and improving leverage preserves financial flexibility for capex, R&D and opportunistic M&A. A stronger equity base and contained debt ratios reduce refinancing risk and support steady investment through industry cycles, enhancing long-term resilience.
Bears Say
Weakening Revenue TrendFlat then sharply declining revenue indicates weakening demand or portfolio challenges. Sustained top-line contraction can erode scale economics, limit funding for innovation, and make maintaining margins and long-term growth targets more difficult without strategic corrective actions.
Declining Return On EquityROE dropping from mid‑teens to ~9% signals reduced capital efficiency and weaker profit generation versus the equity base. Over months this can constrain shareholder returns, reflect competitive pressure or heavier capital intensity, and limit the attractiveness of incremental equity investment.
Only Moderate Cash ConversionWhile FCF improved recently, conversion remains moderate: FCF at ~50–70% of net income limits internally available funds. This reduces the company's ability to self-fund growth, dividends or buybacks consistently, increasing dependence on external financing in stress periods.
MRK FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was €100.70 and its highest was €148.65 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is €60.74B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Aug 06, 2026 which is in 22 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on May 13, 2026. The company reported €2.11 earnings per share for the quarter, beating the consensus estimate of €1.947 by €0.163.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA pays a Annually dividend of €2.2 which represents an annual dividend yield of 1.82%. See more information on Merck KGaA dividends here
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 2.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of €2.11 in its last earnings report, beating expectations of €1.947. Following the earnings report the stock price went up 7.212%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in DE:MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.96%
12-Months-Change
Fundamentals
Return on Equity
8.77%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
MRK Stock 12 Month Forecast
Average Price Target
€141.14
▲(19.11% Upside)
Technical Analysis
Evotec
―
Fresenius SE & Co. KGaA
―
Sartorius
―
Dermapharm Holding SE
―
Siemens Healthineers AG
―
Options Prices
Currently, No data available
---